$13.02
0.15% today
Nasdaq, Feb 05, 04:15 pm CET
ISIN
US30052C1071
Symbol
EOLS
Sector
Industry

Evolus, Inc. Stock price

$13.00
+2.00 18.18% 1M
-0.31 2.33% 6M
+1.96 17.75% YTD
+0.23 1.80% 1Y
+4.62 55.13% 3Y
+2.61 25.12% 5Y
+1.50 13.04% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.02 0.15%
ISIN
US30052C1071
Symbol
EOLS
Sector
Industry

Key metrics

Market capitalization $823.18m
Enterprise Value $868.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.50
P/S ratio (TTM) P/S ratio 3.31
P/B ratio (TTM) P/B ratio 139.60
Revenue growth (TTM) Revenue growth 34.43%
Revenue (TTM) Revenue $248.33m
EBIT (operating result TTM) EBIT $-31.57m
Free Cash Flow (TTM) Free Cash Flow $-23.24m
Cash position $85.04m
EPS (TTM) EPS $-0.91
P/E forward negative
P/S forward 3.09
EV/Sales forward 3.26
Short interest 9.57%
Show more

Is Evolus, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Evolus, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Evolus, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Evolus, Inc. forecast:

Buy
100%

Financial data from Evolus, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
248 248
34% 34%
100%
- Direct Costs 80 80
32% 32%
32%
168 168
35% 35%
68%
- Selling and Administrative Expenses 185 185
21% 21%
75%
- Research and Development Expense 9.12 9.12
65% 65%
4%
-26 -26
25% 25%
-10%
- Depreciation and Amortization 5.77 5.77
3% 3%
2%
EBIT (Operating Income) EBIT -32 -32
21% 21%
-13%
Net Profit -55 -55
12% 12%
-22%

In millions USD.

Don't miss a Thing! We will send you all news about Evolus, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evolus, Inc. Stock News

Positive
Investors Business Daily
15 days ago
Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025. The post Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why appeared first on Investor's Business Daily.
Neutral
Business Wire
15 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available to manag...
Neutral
Business Wire
19 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committ...
More Evolus, Inc. News

Company Profile

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Head office United States
CEO David Moatazedi
Employees 273
Founded 2012
Website www.evolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today